These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 37184290)

  • 21. Tralokinumab for moderate-to-severe atopic dermatitis: results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials (ECZTRA 1 and ECZTRA 2).
    Wollenberg A; Blauvelt A; Guttman-Yassky E; Worm M; Lynde C; Lacour JP; Spelman L; Katoh N; Saeki H; Poulin Y; Lesiak A; Kircik L; Cho SH; Herranz P; Cork MJ; Peris K; Steffensen LA; Bang B; Kuznetsova A; Jensen TN; Østerdal ML; Simpson EL;
    Br J Dermatol; 2021 Mar; 184(3):437-449. PubMed ID: 33000465
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Early Itch Response with Abrocitinib Is Associated with Later Efficacy Outcomes in Patients with Moderate-to-Severe Atopic Dermatitis: Subgroup Analysis of the Randomized Phase III JADE COMPARE Trial.
    Ständer S; Kwatra SG; Silverberg JI; Simpson EL; Thyssen JP; Yosipovitch G; Zhang F; Cameron MC; Cella RR; Valdez H; DiBonaventura M; Feeney C
    Am J Clin Dermatol; 2023 Jan; 24(1):97-107. PubMed ID: 36512175
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial.
    Simpson EL; Sinclair R; Forman S; Wollenberg A; Aschoff R; Cork M; Bieber T; Thyssen JP; Yosipovitch G; Flohr C; Magnolo N; Maari C; Feeney C; Biswas P; Tatulych S; Valdez H; Rojo R
    Lancet; 2020 Jul; 396(10246):255-266. PubMed ID: 32711801
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy and Safety of Dupilumab in Patients With Erythrodermic Atopic Dermatitis: A Post Hoc Analysis of 6 Randomized Clinical Trials.
    Paller AS; Silverberg JI; Cork MJ; Guttman-Yassky E; Lockshin B; Irvine AD; Kim MB; Kabashima K; Chen Z; Lu Y; Bansal A; Rossi AB; Shabbir A
    JAMA Dermatol; 2023 Mar; 159(3):255-266. PubMed ID: 36723913
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Characterization of acne associated with upadacitinib treatment in patients with moderate-to-severe atopic dermatitis: A post hoc integrated analysis of 3 phase 3 randomized, double-blind, placebo-controlled trials.
    Mendes-Bastos P; Ladizinski B; Guttman-Yassky E; Jiang P; Liu J; Prajapati VH; Simpson EL; Vigna N; Teixeira HD; Barbarot S
    J Am Acad Dermatol; 2022 Oct; 87(4):784-791. PubMed ID: 35714786
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The efficacy and safety of upadacitinib treatment for moderate to severe atopic dermatitis in real-world practice in Japan.
    Hagino T; Saeki H; Kanda N
    J Dermatol; 2022 Nov; 49(11):1158-1167. PubMed ID: 35986480
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effectiveness of Dose Increase in Upadacitinib from 15 mg to 30 mg for Patients with Moderate-to-Severe Atopic Dermatitis: A Real-World Clinical Practice in Japan.
    Hagino T; Hamada R; Yoshida M; Saeki H; Fujimoto E; Kanda N
    Clin Drug Investig; 2024 Apr; 44(4):261-269. PubMed ID: 38446396
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinically Meaningful Responses to Dupilumab in Adolescents with Uncontrolled Moderate-to-Severe Atopic Dermatitis: Post-hoc Analyses from a Randomized Clinical Trial.
    Paller AS; Bansal A; Simpson EL; Boguniewicz M; Blauvelt A; Siegfried EC; Guttman-Yassky E; Hultsch T; Chen Z; Mina-Osorio P; Lu Y; Rossi AB; He X; Kamal M; Graham NMH; Pirozzi G; Ruddy M; Eckert L; Gadkari A
    Am J Clin Dermatol; 2020 Feb; 21(1):119-131. PubMed ID: 31823222
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dupilumab Provides Acceptable Safety and Sustained Efficacy for up to 4 Years in an Open-Label Study of Adults with Moderate-to-Severe Atopic Dermatitis.
    Beck LA; Deleuran M; Bissonnette R; de Bruin-Weller M; Galus R; Nakahara T; Seo SJ; Khokhar FA; Vakil J; Xiao J; Marco AR; Levit NA; O'Malley JT; Shabbir A
    Am J Clin Dermatol; 2022 May; 23(3):393-408. PubMed ID: 35503163
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy and Safety of Tralokinumab in Adolescents With Moderate to Severe Atopic Dermatitis: The Phase 3 ECZTRA 6 Randomized Clinical Trial.
    Paller AS; Flohr C; Cork M; Bewley A; Blauvelt A; Hong HC; Imafuku S; Schuttelaar MLA; Simpson EL; Soong W; Arlert P; Lophaven KW; Kurbasic A; Soldbro L; Vest NS; Wollenberg A
    JAMA Dermatol; 2023 Jun; 159(6):596-605. PubMed ID: 37074705
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Real-Life Effectiveness and Tolerance of Upadacitinib for Severe Atopic Dermatitis in Adolescents and Adults.
    De Greef A; Ghislain PD; de Montjoye L; Baeck M
    Adv Ther; 2023 May; 40(5):2509-2514. PubMed ID: 36944819
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Real-world Experience of Abrocitinib Treatment in Patients with Atopic Dermatitis and Hand Eczema: Up to 28-week Results from the BioDay Registry.
    Kamphuis E; Boesjes CM; Loman L; Kamsteeg M; Haeck I; Van Lynden-van Nes AMT; Politiek K; Van der Gang LF; De Graaf M; De Bruin-Weller MS; Schuttelaar MLA
    Acta Derm Venereol; 2024 Feb; 104():adv19454. PubMed ID: 38323500
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Exposure-Response Analyses for Upadacitinib Efficacy in Subjects With Atopic Dermatitis-Analyses of Phase 2b Study to Support Selection of Phase 3 Doses.
    Mohamed MF; Gopalakrishnan S; Teixeira HD; Othman AA
    J Clin Pharmacol; 2021 May; 61(5):628-635. PubMed ID: 33156550
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy and safety of baricitinib in combination with topical corticosteroids in patients with moderate-to-severe atopic dermatitis with inadequate response, intolerance or contraindication to ciclosporin: results from a randomized, placebo-controlled, phase III clinical trial (BREEZE-AD4).
    Bieber T; Reich K; Paul C; Tsunemi Y; Augustin M; Lacour JP; Ghislain PD; Dutronc Y; Liao R; Yang FE; Brinker D; DeLozier AM; Meskimen E; Janes JM; Eyerich K;
    Br J Dermatol; 2022 Sep; 187(3):338-352. PubMed ID: 35484697
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long-Term Efficacy and Safety of Dupilumab in Adolescents with Moderate-to-Severe Atopic Dermatitis: Results Through Week 52 from a Phase III Open-Label Extension Trial (LIBERTY AD PED-OLE).
    Blauvelt A; Guttman-Yassky E; Paller AS; Simpson EL; Cork MJ; Weisman J; Browning J; Soong W; Sun X; Chen Z; Kosloski MP; Kamal MA; Delevry D; Chuang CC; O'Malley JT; Bansal A
    Am J Clin Dermatol; 2022 May; 23(3):365-383. PubMed ID: 35567671
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Upadacitinib effectiveness in moderate-to-severe atopic dermatitis: A real-life multicentre and retrospective study.
    Melgosa Ramos FJ; González-Delgado V; Motilla JMS; Marta GP; Mateu Puchades A; Sergio SA
    Australas J Dermatol; 2023 Nov; 64(4):e361-e364. PubMed ID: 37743698
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Long-term Efficacy of Baricitinib in Adults With Moderate to Severe Atopic Dermatitis Who Were Treatment Responders or Partial Responders: An Extension Study of 2 Randomized Clinical Trials.
    Silverberg JI; Simpson EL; Wollenberg A; Bissonnette R; Kabashima K; DeLozier AM; Sun L; Cardillo T; Nunes FP; Reich K
    JAMA Dermatol; 2021 Jun; 157(6):691-699. PubMed ID: 33978711
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Responsiveness and interpretability of the Hand Eczema Severity Index.
    Oosterhaven JAF; Schuttelaar MLA
    Br J Dermatol; 2020 Apr; 182(4):932-939. PubMed ID: 31260086
    [TBL] [Abstract][Full Text] [Related]  

  • 39. More Time Spent with Clear Skin and No Itch with Upadacitinib versus Dupilumab for Atopic Dermatitis.
    Blauvelt A; Eyerich K; Irvine AD; de Bruin-Weller M; Kwatra SG; Gooderham M; Kim B; Calimlim BM; Lee WJ; Raymundo EM; Liu Y; Ofori S; Platt AM; Silverberg JI
    Dermatol Ther (Heidelb); 2024 Sep; 14(9):2621-2630. PubMed ID: 39110139
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy and Safety of Oral Janus Kinase 1 Inhibitor Abrocitinib for Patients With Atopic Dermatitis: A Phase 2 Randomized Clinical Trial.
    Gooderham MJ; Forman SB; Bissonnette R; Beebe JS; Zhang W; Banfield C; Zhu L; Papacharalambous J; Vincent MS; Peeva E
    JAMA Dermatol; 2019 Dec; 155(12):1371-1379. PubMed ID: 31577341
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.